Skip to main content

Demonstration of NOPERSIST results leading to novel, validated diagnostic tests for active human and bovine tuberculosis

Objective

Tuberculosis (TB) in humans and bovine TB in farm animals are global health problems of immense social and economic importance.

Human TB: Mycobacterium tuberculosis (M.tb) is a slowly replicating bacillus that resides intracellularly within phagosomes of macrophages and commonly causes latent infections of the lung and in about 5% of the infected individuals it leads to active disease. Co-infection with M. tuberculosis is estimated in about one-third of HIV-1 infected subjects. Indeed, the risk of developing M. tuberculosis as an opportunistic infection is increased up to 200-fold in HIV-1+ subjects. Drug resistance to HIV-treatment and appearance of multiple-drug resistance (MDR) and off late of Extra-Drug Resistance (XDR) strains of M. tuberculosis, the causative agent of human TB is steadily leading to a hopeless situation as far as the therapy is concerned.Bovine TB: Bovine tuberculosis is caused by the bacterium Mycobacterium bovis, which is closely related to Mycobacterium tuberculosis, the cause of human tuberculosis. M. bovis can be transmitted to humans through the ingestion of unpasteurised milk and milk products as well as aerosols, from infected cows. The introduction of pasteurisation eliminated transmission through contaminated milk and greatly reduced the human health problem1. The principal hosts for bovine tuberculosis are cattle and buffalo, however many other domestic and wild animals can become infected e.g. goats, cervids, pigs, wild boars, dogs, cats, camels, badgers, primates, hares, amongst others. Bovine tuberculosis is found worldwide. All developed countries currently have a TB eradication program in place for many years. These programs have been largely successful; however, incidences are increasing in many countries (e.g. UK, Ireland, France, Austria, Germany).
The specific objectives achievable within DEMO-NOPERSIST project are

1. Development and evaluation of prototype test kits for active human TB (LIONEX, SME). This test shall be the World’s first blood test for discriminating latent from active TB in humans.

2. Development and evaluation of prototype test kits for active Bovine TB (PRIONICS, SME)

3. To develop marketable, improved diagnostic products for human and bovine TB within a period of 2-3 years .

Thus, both human and bovine active TB tests are directly linked to the NOPERSIST project and shall be an excellent demonstration of a Res4SME project NOPERSIST.

Field of science

  • /medical and health sciences/basic medicine/pharmacology and pharmacy/drug resistance
  • /agricultural sciences/animal and dairy science/pets
  • /social sciences/sociology/anthropology/physical anthropology
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/drug resistance/multidrug resistance
  • /medical and health sciences/clinical medicine/pneumology/tuberculosis
  • /natural sciences/biological sciences/zoology/mammalogy/primatology

Call for proposal

FP7-SME-2013
See other projects for this call

Funding Scheme

CP - Collaborative project (generic)

Coordinator

LIONEX GMBH
Address
Salzdahlumer Strasse 196
38126 Braunschweig
Germany
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 247 920
Administrative Contact
Mahavir Singh (Prof.)

Participants (3)

PRIONICS AG
Switzerland
EU contribution
€ 47 280
Address
Wagistrasse 27 A
8952 Schlieren
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Alex Raeber (Dr.)
UNIVERSITA DEGLI STUDI DI FIRENZE
Italy
EU contribution
€ 66 400
Address
Piazza San Marco 4
50121 Florence
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Mario Milco D'elios (Dr.)
Food and Environment Research Agency
United Kingdom
EU contribution
€ 10 400
Address
Area 1A, Nobel House, Smith Square 17
SW1P 3JR London
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Lucinda Cranham (Mrs.)